About the Study

Hematologic Malignancies or Solid Tumors- A study using Zilovertamab Vedotin (MK-2140) in patients with hematologic malignancies or solid tumors

This study has 2 parts and is for patients who: • Have been diagnosed with relapsed (has come back)/refractory (has not responded to earlier treatment) hematologic malignancies or solid tumor • Part 1: - Are greater than 1 year old and less than 18 years old • Part 2: - Are greater than 6 months old and under 18 years old (May be up to 25 years old with Ewing sarcoma) Part 1 is testing different doses of Zilovertamab Vedotin (MK-2140) to find a recommended dose. Parts 2 is testing the recommended dose once a recommended dose has been found in Part 1. This study is testing the safety, effectiveness, and how well your body handles the drug.

This study does not take place at Children’s Mercy.

Interested in learning more?

Full Study Name: MK9999-01A